Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel

Aharona Glatman-Freedman; Yael Hershkovitz; Rita Dichtiar; Alina Rosenberg; Lital Keinan-Boker; Michal Bromberg

doi:10.3201/eid2904.221285

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel

Aharona Glatman-Freedman, Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, Michal Bromberg

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.

Original language	English
Pages (from-to)	771-777
Number of pages	7
Journal	Emerging Infectious Diseases
Volume	29
Issue number	4
DOIs	https://doi.org/10.3201/eid2904.221285
State	Published - Apr 2023

Bibliographical note

Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid2904.221285

Cite this

@article{fc622444a7e242c89752f41fc0b73787,

title = "Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel",

abstract = "We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.",

author = "Aharona Glatman-Freedman and Yael Hershkovitz and Rita Dichtiar and Alina Rosenberg and Lital Keinan-Boker and Michal Bromberg",

year = "2023",

month = apr,

doi = "10.3201/eid2904.221285",

language = "English",

volume = "29",

pages = "771--777",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "4",

}

TY - JOUR

T1 - Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel

AU - Glatman-Freedman, Aharona

AU - Hershkovitz, Yael

AU - Dichtiar, Rita

AU - Rosenberg, Alina

AU - Keinan-Boker, Lital

AU - Bromberg, Michal

PY - 2023/4

Y1 - 2023/4

N2 - We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.

AB - We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.

UR - http://www.scopus.com/inward/record.url?scp=85150606239&partnerID=8YFLogxK

U2 - 10.3201/eid2904.221285

DO - 10.3201/eid2904.221285

M3 - Article

C2 - 36863005

AN - SCOPUS:85150606239

SN - 1080-6040

VL - 29

SP - 771

EP - 777

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 4

ER -

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this